Background: Contemporary information on health equity related efforts by scientific neurological journals, as measured by publications related to diversity, equity and inclusion (DEI) and health disparities related to social determinants of health (SDH) are lacking.
Objective: To assess the yearly rates of DEI and SDH related publications in the highest cited general neurology and neurological sub-specialty journals and compare them to the highest cited medical journals over a 6-year period.
Methods: We included publications from 15 general neurology and neurological subspecialty journals between January 1 2015 to December 31 2020. For comparison we included the 15 most cited medical journals as measured by H-Index. We performed a PubMed search in each of the listed journals using key MeSH terms. Two-proportions Z-test and chi-square trend analyses were used to compare differences between journal types.
Results: Total yearly proportion of DEI and SDH related publications in neurological journals was 3.9% compared to 6.2% in the highest cited medical journals for years 2015 to 2020 (p=0.001). There was no change in overall trend in publications related to DEI and SDH topics in neurological (ρ = -0.082, p=0.45) or highest cited medical journals between 2015 and 2020 (ρ = -0.065, p=0.54).
Conclusion: Neurological journals had a significantly lower yearly proportion of DEI and SDH related publications compared to top-cited medical journals. Despite heightened awareness of racial/ethnic health disparities and inequities driven by SDH there was no change in related publications in neurological journals between 2015-2020.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jnma.2022.09.008 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Negative impact of self-reported executive problems in patients with functional/dissociative seizures: Results from a prospective long-term observational study.
Seizure
January 2025
The National Centre for Epilepsy, Division of Clinical Neuroscience, Full Member of European Reference Network on Rare and Complex Epilepsies EpiCARE, Oslo University Hospital, Oslo, Norway; Institute of Clinical Medicine, University of Oslo, Oslo, Norway.
Objective: Functional/dissociative seizures (FDS) are common and pose a considerable burden on both individual patients and healthcare systems. Cognitive complaints are frequent in patients with FDS. Previous studies on cognitive function in patients with FDS have yielded mixed results.
View Article and Find Full Text PDFThe Internet of Things in the Nutritional Management of Patients with Chronic Neurological Cognitive Impairment: A Scoping Review.
Healthcare (Basel)
December 2024
Units of Diabetology, ASUR Marche, 63900 Fermo, Italy.
Background/objectives: The Internet of Things (IoT) technology connects objects to the internet, and its applications are increasingly used in healthcare to improve the quality of care. However, the use of IoT for the nutritional management of patients with chronic neurological cognitive impairment is still in development. This scoping review aims to describe the integration of IoT and its applications to support monitoring, interventions, and nutritional education for patients with chronic neurological cognitive impairment.
View Article and Find Full Text PDFResearch Hotspots and Trends in the Antioxidant Effects of Acupuncture: A Bibliometric analysis from 2003 to 2024.
Complement Ther Med
January 2025
The First Clinical Medical College of Yunnan University of Traditional Chinese Medicine, Yunnan Provincial Hospital of Traditional Chinese Medicine, Kunming, China; Yunnan University of Chinese Medicine, Kunming, China. Electronic address:
Objective: Oxidative stress is an important factor mediating the pathologic progression of many diseases. In recent years, the antioxidant effects of acupuncture have been gradually confirmed. However, bibliometric analysis in this field, which is still lacking.
View Article and Find Full Text PDF: Welcoming a New Member of the Family of Journals.
Neurology
February 2025
Department of Neurology, Georgetown University School of Medicine, Washington, DC.
Who will benefit from vorasidenib? Review of data from the literature and open questions.
Neurooncol Pract
February 2025
Department of Neurological Surgery, University of California San Francisco and Weill Institute for Neurosciences, San Francisco, California, USA.
The clinical efficacy of isocitrate dehydrogenase (IDH) inhibitors in the treatment of patients with grade 2 IDH-mutant (mIDH) gliomas is a significant therapeutic advancement in neuro-oncology. It expands treatment options beyond traditional radiation therapy and cytotoxic chemotherapy, which may lead to significant long-term neurotoxic effects while extending patient survival. The INDIGO study demonstrated that vorasidenib, a pan-mIDH inhibitor, improved progression-free survival for patients with grade 2 mIDH gliomas following surgical resection or biopsy compared to placebo and was well tolerated.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!